Eikon Therapeutics director granted 25,873 options

FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.

Eikon Therapeutics director Kenneth C. Frazier reported a new stock option grant covering 25,873 shares of Eikon Therapeutics common stock on March 2, 2026. The option vests in equal monthly installments over 48 months, conditioned on his continued service with the company.

Insider Trade Summary

Grant/Award: 25,873 shares

Grant/Award 1 txn

Insider FRAZIER KENNETH C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,873	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 25,873 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eikon Therapeutics (EIKN) director Kenneth C. Frazier report on this Form 4?

Kenneth C. Frazier reported receiving a stock option grant for 25,873 shares of Eikon Therapeutics common stock. The option was granted on March 2, 2026 and is structured as a long-term equity incentive award rather than an open-market stock purchase or sale.

How many Eikon Therapeutics shares are covered by the new stock option grant?

The stock option grant reported by Kenneth C. Frazier covers 25,873 shares of Eikon Therapeutics common stock. This entire amount is reflected as the total number of derivative securities beneficially owned by him following the transaction on the Form 4 insider trading report.

How does the stock option granted to EIKN director Kenneth C. Frazier vest?

The option vests in 48 equal monthly installments, with 1/48th of the underlying shares vesting on each monthly anniversary of the vesting start date. Vesting occurs only if Kenneth C. Frazier continues to provide service to Eikon Therapeutics through each applicable vesting date.

Was the Form 4 transaction for Eikon Therapeutics stock a purchase or a grant?

The Form 4 reports a grant or award acquisition of stock options, not an open-market stock purchase. The transaction code is “A,” which indicates a grant, award, or other acquisition of derivative securities rather than a standard buy or sell transaction in the company’s common shares.

Does Kenneth C. Frazier directly own the stock options reported for Eikon Therapeutics (EIKN)?

Yes, the Form 4 indicates that Kenneth C. Frazier holds the stock option directly. The ownership code is listed as “D” for direct ownership, and there is no footnote stating that the options are held through another entity, trust, or family investment vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRAZIER KENNETH C

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		25,873		(1)	03/01/2036	Common Stock	25,873	$0	25,873	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

	/s/ Benjamin Thorner, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.